Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,759.80up ₹25.40 (0.68%)BSE ₹3,760.40
Share price at the NSE close on 29 Oct 2026. Previous close ₹3,734.40.
29 Oct: open ₹3,749.00, high ₹3,799.00, low ₹3,732.30
52-week range of traded prices to 29 Oct 2026
₹3,589.00Low, 23 Oct 2026₹5,346.00High, 30 Oct 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,200 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 23.40
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.99%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,53757.2% delivered
Pfizer board and management
56 filed, newest first. Page 2 of 2.
May 2012
21 May · Management
Dr. Bomi M. Gagrat, Non-Executive Director has resigned from the Board of Directors of the Company with effect from the close of business hours on May 21, 2012.21 May · Management
Board of Directors of the Company at their meeting held on May 21, 2012 appointed the following Additional Directors on the Board of the Company with effect from May 21, 2012: (1) Mr. Uday Khanna; (2) Mr. Sunil Madhok, designated as Executive Director, Business Operations; (3) Mr. Vivek Dhariwal, designated as Executive Director, Technical Operations. The appointment and remuneration of Mr. Madhok and Mr. Dhariwal, Whole-time Directors will be subject to the approval of the shareholders in the ensuing Annual General Meeting of the Company.
Jan 2011
11 Jan · Management
Mr. Richard Gane has resigned as a Director of the Company with effect from close of business on January 11, 2011.
Apr 2008
29 Apr · Management
Pfizer Ltd. has informed the Exchange that: "Mr. Yugesh Goutam, Executive Director, Human Resources, has resigned from the Board of Pfizer Ltd. effective from the close of business hours of 28th April, 2008".
Sep 2007
3 Sep · Management
Pfizer Ltd. has informed the Exchange that "Mr. K. Subharaman, Company Secretary, has ceased to be in the employment of the Company with effect from the close of business on August 31, 2007. Accordingly, he also ceased to be the Compliance Officer of the Company with effect from the said date. Mr. Prajeet Nair has been appointed as the Company Secretary with effect from September 1, 2007. Mr. Nair will act as the Compliance Officer of the Company with effect from the said date".
Jul 2007
3 Jul · Management
Pfizer Ltd. has informed the Exchange that the Board of Directors in its meeting held on June 28, 2007 have appointed Mr. Yugesh Goutam, Senior Director-Human Resources (HR) as Additional Director on the Board of Pfizer Ltd.